A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

NCT02042885 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Salivary Gland Cancer
Endometrial Cancer
Squamous Cell Carcinoma of the Cervix
Breast Cancer
Ovarian Cancer

Interventions

DRUG: OPB-111001

Sponsor

Otsuka Novel Products GmbH